RxDoctor Payments Data

Ryan Simonak, DO

Family Medicine · Fort Worth, TXNPI 1871721993

Payments from drug & device makers

$10,216in general payments, 2019–2025

Across 638 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$944
  • Abbott$711
  • Boehringer Ingelheim$702
  • Pfizer$615
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$598
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$10,196100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)108$1,485
Lilly USA, LLC69$944
Abbott34$711
Boehringer Ingelheim41$702
Pfizer37$615
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$598
AstraZeneca38$575
Bayer25$414
GSK19$389
Novo Nordisk28$384
Amgen(2 entities)23$353
Kowa Pharmaceuticals America, Inc.18$259
Amarin Pharma, Inc.9$177
Avvisto Therapeutics, LLC11$175
Biohaven Pharmaceutical Holding Company Ltd.8$144
Corium, LLC5$139
Merck10$138
Endo Pharmaceuticals Inc.8$135
Astellas Pharma US Inc7$122
Johnson & Johnson(2 entities)7$118
Takeda Pharmaceuticals U.S.A., Inc.7$111
Eisai Inc.5$99
Biohaven Pharmaceuticals, Inc.5$89
Otsuka America Pharmaceutical, Inc.5$87
Sanofi Pasteur Inc.4$79
Genentech USA, Inc.5$73
Supernus Pharmaceuticals, Inc.4$65
Currax Pharmaceuticals LLC5$64
Exact Sciences3$63
Idorsia Pharmaceuticals US Inc4$62
Gilead4$59
IBSA Pharma Inc.3$58
Acella Pharmaceuticals, LLC3$57
Ironshore Pharmaceuticals Inc.3$51
Esperion Therapeutics, Inc.3$48
Teva Pharmaceuticals USA, Inc.3$48
Sanofi-aventis U.S. LLC3$43
Shire North American Group Inc3$43
Bioventus LLC2$37
Tris Pharma Inc2$34
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$32
Kaleo, Inc.2$29
Azurity Pharmaceuticals, Inc.2$27
Novartis2$27
Amneal Pharmaceuticals LLC1$24
Endo USA, Inc.1$24
Nevro Corp.1$23
Optinose US, Inc.1$21
Nestle Healthcare Nutrition Inc.1$21
Dexcom, Inc.1$20
Phathom Pharmaceuticals, Inc.1$15
Adlon Therapeutics L.p.1$15
Silk Road Medical, Inc.1$15
Arbor Pharmaceuticals, Inc.1$15
Mannkind Corporation1$14
Seqirus USA Inc1$13
Althera Pharmaceuticals LLC1$12
Galderma Laboratories, L.p.1$12
Paratek Pharmaceuticals, Inc.1$12

How this compares

$10,216 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$231,403
Medicare patients
438
Services billed
47,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$113,342
JardianceEmpagliflozin68$89,703
MounjaroTirzepatide58$82,736
EliquisApixaban58$64,048
JanuviaSitagliptin Phosphate34$49,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$29,837
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$28,474
TrulicityDulaglutide20$21,964
XareltoRivaroxaban17$18,879
MyrbetriqMirabegron27$18,037
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$15,509
EntrestoSacubitril/Valsartan13$12,867
Breo ElliptaFluticasone/Vilanterol13$7,435
Liothyronine Sodium143$6,603
Levothyroxine Sodium289$3,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$384$113,342106 claims
Lilly USA, LLCMounjaro, Trulicity$944$104,70078 claims
Boehringer IngelheimJardiance$702$89,70368 claims
PfizerEliquis$615$64,04858 claims
MerckJanuvia$138$49,01234 claims
GSKTrelegy Ellipta, Breo Ellipta$389$37,27245 claims
Johnson & JohnsonXarelto$118$18,87917 claims
Astellas Pharma US IncMyrbetriq$122$18,03727 claims
AstraZenecaBreztri Aerosphere$575$15,50912 claims
NovartisEntresto$27$12,86713 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$3,513289 claims
AbbVieSynthroid, Armour Thyroid$1,485$2,51131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →